Cosmos Health Posts Record $54.3M Nine-Month Revenue, Reaffirms $90M+ 2026 Outlook
COSM has more than doubled off its 52-week low of $0.162 on light trading volume (0.1× avg).
Summary
Cosmos Health reported preliminary nine-month revenue of $54.3M, up 19% year-over-year, and record Q3 revenue of $17.4M. The company reaffirmed its full-year 2026 outlook of over $90M, implying Q4 revenue of roughly $35.7M—a significant step-up from Q3. This follows record Q2 revenue of $18.99M reported in August, but the company's Q2 net loss doubled to $6.09M with going concern doubt reiterated. The revenue growth is broad-based across contract manufacturing, distribution, and proprietary brands. The reaffirmed outlook suggests management expects a strong Q4, but profitability remains a concern given the recent loss trend.
Updates
· SEC 8-K — Cosmos Health reported record preliminary nine-month 2026 revenue of $54.3 million, up 19% from $45.6 million in 2025, and reaffirmed its full-year 2026 outlook of over $90 million.
- Revenue Comparisons — Nine-month 2026 revenue increased by $8.7 million from $45.6 million in 2025, nearly matches full-year 2024 revenue of $54.4 million, and represents 83% of full-year 2025 revenue of $65.3 million. Nine-month 2026 revenue increased 35% compared to the first nine months of 2024. Full-year 2026 outlook of over $90 million represents 65% growth over 2024.
- Quarterly Records — Q3 2026 revenue exceeded the previous Q3 record of $17.1 million set in 2025, was up 2% on Q3 2025 and up 40% on Q3 2024 revenue of $12.4 million. Every quarter of 2026 (Q1, Q2, Q3) has set a record for its period.
- Growth Drivers
- Contract manufacturing at Cana Laboratories reached a record pipeline of over 32.7 million units.
- Pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand.
- Proprietary brands include Sky Premium Life, C-Scrub, and C-Sept.
- Proprietary brands grew in their established markets and entered new territories and channels globally.
- Sales momentum in the United States continued to build.
- Q4 strength supported by contract manufacturing orders, seasonal strength in distribution, and accelerating sales in the United States.
- Outlook — Full-year 2026 outlook of over $90 million would represent 38% growth over 2025. The fourth quarter of 2026 is expected to be the strongest in the company's history.
- Preliminary Nature — Preliminary figures are unaudited, based on information available to management as of the date of the release, and remain subject to the completion of quarter-end financial closing procedures and review; actual results may differ.
All 23 details
- Nine-month 2026 revenue increased by $8.7 million from the same period of 2025.
- Nine-month 2025 revenue was $45.6 million.
- Nine-month 2026 revenue nearly matches full-year 2024 revenue of $54.4 million.
- Nine-month 2026 revenue represents 83% of full-year 2025 revenue of $65.3 million.
- Full-year 2025 revenue was $65.3 million.
- Full-year 2024 revenue was $54.4 million.
- Q3 2026 revenue exceeded the previous Q3 record of $17.1 million set in 2025.
- Q3 2025 revenue was $17.1 million.
- Q3 2026 revenue was up 2% on Q3 2025.
- Q3 2026 revenue was up 40% on Q3 2024.
- Q3 2024 revenue was $12.4 million.
- Every quarter of 2026 (Q1, Q2, Q3) has set a record for its period.
- Full-year 2026 outlook of over $90 million would represent 38% growth over 2025.
- The fourth quarter of 2026 is expected to be the strongest in the company's history.
- Contract manufacturing at Cana Laboratories reached a record pipeline of over 32.7 million units.
- Pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand.
- Proprietary brands include Sky Premium Life, C-Scrub, and C-Sept.
- Proprietary brands grew in their established markets and entered new territories and channels globally.
- Sales momentum in the United States continued to build.
- Q4 strength supported by contract manufacturing orders, seasonal strength in distribution, and accelerating sales in the United States.
- Preliminary figures are unaudited, based on information available to management as of the date of the release, and remain subject to the completion of quarter-end financial closing procedures and review; actual results may differ.
- Nine-month 2026 revenue increased 35% compared to the first nine months of 2024.
- Full-year 2026 revenue outlook of over $90 million represents 65% growth over 2024.
At the time of this announcement, COSM was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.8M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.